Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin MD on a biosimilars play fused around Japan 'anchor'

This article was originally published in Scrip

Executive Summary

Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a strategy centred around its "anchor market" Japan may more than compensate as well as propelling its entry into the US and Europe.

Advertisement

Related Content

Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge
Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028770

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel